PTJ
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


First published on November 6, 2007

Physical Therapy 2008;88:105.

Physical Therapy
DOI: 10.2522/ptj.20070104

This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
ptj.20070104v1
88/1/105    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Rapid Responses are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pandya, S.
Right arrow Articles by Tawil, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pandya, S.
Right arrow Articles by Tawil, R.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Update

Facioscapulohumeral Dystrophy

Shree Pandya, Wendy M King and Rabi Tawil

S Pandya, PT, MS, is Assistant Professor of Neurology and Physical Medicine and Rehabilitation, School of Medicine and Dentistry, University of Rochester, Rochester, NY 14627 (USA).
WM King, PT, BA, is Clinical Assistant Professor of Neurology, Department of Neurology, Ohio State University, Columbus, Ohio.
R Tawil, MD, is Professor of Neurology, Department of Neurology, University of Rochester.

shree_pandya{at}urmc.rochester.edu

Facioscapulohumeral dystrophy (FSHD) is the third most common inherited muscular dystrophy after Duchenne dystrophy and myotonic dystrophy. Over the last decade, major advances have occurred in the understanding of the genetics of this disorder. Despite these advances, the exact mechanisms that lead to atrophy and weakness secondary to the genetic defect are still not understood. The purposes of this article are to increase awareness of FSHD among clinicians; to provide an update regarding the genetics, clinical features, natural history, and current management of FSHD; and to discuss opportunities for research.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Proc. Natl. Acad. Sci. USAHome page
P. Arashiro, I. Eisenberg, A. T. Kho, A. M. P. Cerqueira, M. Canovas, H. C. A. Silva, R. C. M. Pavanello, S. Verjovski-Almeida, L. M. Kunkel, and M. Zatz
Transcriptional regulation differs in affected facioscapulohumeral muscular dystrophy patients compared to asymptomatic related carriers
PNAS, April 14, 2009; 106(15): 6220 - 6225.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2007 by the American Physical Therapy Association.